LindaT.VahdatMDMBA

Oncology • Lebanon, NH

Breast Cancer

Chief of Cancer Services Memorial Sloan Kettering -Norwalk Hospital Partnership Professor of Medicine, Weill Cornell medicine

Join to view full profile

Dr. Vahdat is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Vahdat's full profile

Already have an account?

Office
1 Medical Center Dr
Lebanon, NH 03756
Phone+1 603-650-5747

Education & Training

Massachusetts Institute of Technology, Sloan School of ManagementMBA, Business, 2012 - 2014
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1991 - 1994
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1987 - 1990
Icahn School of Medicine at Mount SinaiClass of 1987

Certifications & Licensure

NH State Medical License 2022 - 2026
VT State Medical License 2023 - 2026
NY State Medical License 1988 - 2025
CT State Medical License 2017 - 2022
American Board of Internal Medicine Medical Oncology

Publications & Presentations

PubMed

Integrative co-registration of elemental imaging and histopathology for enhanced spatial multimodal analysis of tissue sections through TRACE.
Yunrui Lu, Serin Han, Aruesha Srivastava, Neha Shaik, Matthew Chan
Bioinformatics Advances. 2025-01-01
A novel network-based method identifies a cuproplasia-related pan-cancer gene signature to predict patient outcome.
Vu Viet Hoang Pham, Toni Rose Jue, Jessica Lilian Bell, Fabio Luciani, Filip Michniewicz
Human Genetics. 2024-10-01
1 citations
Evolving Management of Breast Cancer in the Era of Predictive Biomarkers and Precision Medicine.
Muhammad Zubair Afzal, Linda T Vahdat
Journal of Personalized Medicine. 2024-07-03

Press Mentions

Copper Depletion Combats Metastatic Recurrence in High-Risk TNBCSeptember 9th, 2024
This Clinical Trial Is Testing a Pill for Triple-Negative Breast CancerAugust 27th, 2024
Post-ASCO News Alert: AstraZeneca’s/Merck’s Lynparza Use in Niche HR+ gBRCA-Mutant Breast Cancer Subgroup Could Compete with VerzenioJune 21st, 2021
Join now to see all

Grant Support

Copper-mediated metabolic reprogramming and ECM alterations in TNBC metastasisWEILL MEDICAL COLL OF CORNELL UNIV2021–2026